Any current/future new fundraising through debt or equity?

The company currently has some debt, which is at its peak as per the latest updates. There are no significant investment plans currently, indicating no immediate need for additional fundraising. Working capital pressure is easing due to the reduction in raw material prices. Interest costs have increased due to higher rupee and foreign exchange rates, but this is considered a part of the current financial environment. The company does not anticipate raising new debt or equity in the near future given the completion of the recent Capex cycle and absence of major upcoming investments.

Any current/future capex/capital investment/strategic investment?

The current Capex cycle has been completed, including the speciality chemical plant at Dahej. No significant new Capex plans at the moment. Focus remains mainly on sulfur chemistry. Some minor investments may be considered on the boron side, but nothing finalized yet. Energy recovery plans at Roha are underway to reduce carbon footprint and dependence on the grid. Capacity is deemed sufficient for the immediate term. Further speciality expansion at Dahej may take longer due to current global uncertainties. The company expects to ramp up new plants over the next few quarters. Overall, no major

Future growth expectations in sales/revenue/volumes?

Completed current Capex cycle with visible revenue potential around ₹500 crores at full capacity (Jeevan Patwa, Page 8). Expect 2x asset turnover from the ₹100 crore Capex phase; overall payback may extend from 3 to 4 years due to war-related disruptions (Kumar Ashish, Rohit Balakrishnan, Page 7 and 10). Speciality chemical plant at Dahej commissioned recently; ramp-up expected over next few quarters, contributing to volume growth (Page 4 and 10). Demand is impacted by global slowdown and geopolitical uncertainty, especially due to the Ukraine war; recovery expected once supply chains stabiliz

Future growth expectations in earnings/operating earnings/profits/EPS?

The company has completed its current Capex cycle, with visible revenue potential of around ₹500 crores at full capacity utilization (Page 8). Payback period may extend from the initially expected 3 years to about 4 years due to the unforeseen war situation in Ukraine impacting demand and costs (Page 7). Specialty chemicals margins are expected to remain stable due to contract-based pricing, while bulk chemicals face volatility in raw material prices (Page 9). Demand slowdown, primarily due to global geopolitical issues and energy crises, is causing deferral in purchases and pressure on margin

Current/ Expected Orderbook/ Pending Orders?

The transcript does not explicitly mention the current or expected order book or pending orders in exact figures. The company has visible customers for its specialty chemicals, indicating confirmed demand. The specialty chemical plant at Dahej was completed and is expected to ramp up over the next few quarters. Demand is currently affected globally due to geopolitical situations, notably in Europe and Ukraine, causing deferment in shipments and lower demand. The company is seeing some deferrals in purchases but expects recovery as supply chains stabilize. There is no specific quantified order

DMCC Speciality Chemicals LtdQ2 FY23Chemicals & Petrochemicals

DMCC Speciality Chemicals Ltd Q2 FY23 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹294.7P/E: 18.4Market Cap: ₹734 CrSector: Chemicals & Petrochemicals

Management growth scorecard

Revenue

Category 4

Margin

Category 3

Fundraise

Order

N/A

Capex

0 of 4 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 4

Completed current Capex cycle with visible revenue potential around ₹500 crores at full capacity (Jeevan Patwa, Page 8).
Expect 2x asset turnover from the ₹100 crore Capex phase; overall payback may extend from 3 to 4 years due to war-related disruptions (Kumar Ashish, Rohit Balakrishnan, Page 7 and 10).
Speciality chemical plant at Dahej commissioned recently; ramp-up expected over next few quarters, contributing to volume growth (Page 4 and 10).
Demand is impacted by global slowdown and geopolitical uncertainty, especially due to the Ukraine war; recovery expected once supply chains stabilize (Page 4, 14).
New product launches (3 in last six months) including sulfur-based products expected to improve revenue contribution (Page 9).
Bulk sulfuric acid capacity doubled (from 1 lakh tons at Roha to additional 1 lakh at Dahej), supporting future volume growth (Page 10-12).
Inventory destocking nearing end; demand expected to revive gradually (Page 7).

Margin guidance

Category 3

The company has completed its current Capex cycle, with visible revenue potential of around ₹500 crores at full capacity utilization (Page 8).
Payback period may extend from the initially expected 3 years to about 4 years due to the unforeseen war situation in Ukraine impacting demand and costs (Page 7).
Specialty chemicals margins are expected to remain stable due to contract-based pricing, while bulk chemicals face volatility in raw material prices (Page 9).
Demand slowdown, primarily due to global geopolitical issues and energy crises, is causing deferral in purchases and pressure on margins, impacting near-term earnings (Pages 13-14).
The company expects recovery as supply chain destocking reaches bottom and markets stabilize, but timing is uncertain and dependent on geopolitical resolutions (Page 6).
No significant new Capex planned immediately; focus remains on ramping up existing specialty plants and energy efficiency (Page 12).

See what DMCC Speciality Chemicals Ltd management said on margin guidance — free account, 30 seconds.

Fundraise plans

The company currently has some debt, which is at its peak as per the latest updates.
There are no significant investment plans currently, indicating no immediate need for additional fundraising.
Working capital pressure is easing due to the reduction in raw material prices.
Interest costs have increased due to higher rupee and foreign exchange rates, but this is considered a part of the current financial environment.
The company does not anticipate raising new debt or equity in the near future given the completion of the recent Capex cycle and absence of major upcoming investments.

Order book

The transcript does not explicitly mention the current or expected order book or pending orders in exact figures.
The company has visible customers for its specialty chemicals, indicating confirmed demand.
The specialty chemical plant at Dahej was completed and is expected to ramp up over the next few quarters.
Demand is currently affected globally due to geopolitical situations, notably in Europe and Ukraine, causing deferment in shipments and lower demand.
The company is seeing some deferrals in purchases but expects recovery as supply chains stabilize.
There is no specific quantified order book or backlog disclosed in the call.

See what DMCC Speciality Chemicals Ltd management said on order book — free account, 30 seconds.

Capex plans

The current Capex cycle has been completed, including the speciality chemical plant at Dahej.
No significant new Capex plans at the moment.
Focus remains mainly on sulfur chemistry.
Some minor investments may be considered on the boron side, but nothing finalized yet.
Energy recovery plans at Roha are underway to reduce carbon footprint and dependence on the grid.
Capacity is deemed sufficient for the immediate term.
Further speciality expansion at Dahej may take longer due to current global uncertainties.
The company expects to ramp up new plants over the next few quarters.
Overall, no major strategic capital investments are planned immediately following the completion of the current Capex.

Track DMCC Speciality Chemicals Ltd — get its next earnings analysis in your feed

How does DMCC Speciality Chemicals Ltd rank vs peers in Chemicals & Petrochemicals?

Pro feature

ThisDMCC Speciality Chemicals Ltd

Rev 4Mar 3

See where DMCC Speciality Chemicals Ltd sits in Chemicals & PetrochemicalsSee which companies these are, and every other name in the sector.Open rankings

How does DMCC Speciality Chemicals Ltd rank in Chemicals & Petrochemicals?

Compare DMCC Speciality Chemicals Ltd against every Chemicals & Petrochemicals company (Q2 FY23) on revenue, margins and earnings-call signals.

View Chemicals & Petrochemicals leaderboard →

What DMCC Speciality Chemicals Ltd's management said in earlier quarters

Others in Chemicals & Petrochemicals this season

POCL Enterprises Ltd (Q1 FY27)
466.03 crores (Page 12, 17, 11) . Key investor presentation takeaways from POCL Enterprises Ltd's Q1 FY27 investor presentation — and how it ranks against secto
Deepak Nitrite Ltd (Q2 FY27)
Q2 FY27 total revenue: ₹3,091 crore, up 61% YoY (Page 1, 4, 5, 6, 10, 11) . Key investor presentation takeaways from Deepak Nitrite Ltd's Q2 FY27 investor prese
Privi Speciality Chemicals Ltd (Q2 FY27)
19,239.47 lakhs (approximately 33.9% growth). Key results statement takeaways from Privi Speciality Chemicals Ltd's Q2 FY27 results statement — and how it ranks
NOCIL Ltd (Q2 FY27)
427 crores . Key investor presentation takeaways from NOCIL Ltd's Q2 FY27 investor presentation — and how it ranks against sector peers.

Compare:vs Solar Industries vs Pidilite Inds.vs SRF Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →